Medtech 2026: North America’s Manufacturing and Trade Strategy in a Shifting Landscape

Executive Summary

The medical technology (medtech) sector is entering a period of accelerated change. Forces such as China’s expanding volume-based procurement (VBP), the migration of procedures to outpatient settings, global supply chain pressures, the rise of GLP-1 therapies, and the emergence of platform-based competition are fundamentally reshaping how medical devices are developed, priced, manufactured, and delivered. For North America, these trends carry direct and strategic consequences. The region’s deeply integrated manufacturing network—anchored by the United States’ innovation ecosystem, Canada’s specialized research strengths, and Mexico’s cost-competitive production base—faces both challenges and opportunities. This article analyzes the key trends outlined in Clarivate’s Medtech Trends to Watch 2026, examining their implications for trade flows, supply chain resilience, foreign direct investment, and long-term industrial competitiveness across the USMCA region.

Introduction

Medical technology remains one of North America’s most strategically important industries. The region accounts for a significant share of global medtech production and consumption, with cross-border supply chains connecting factories in Tijuana, Monterrey, Minneapolis, and Toronto. However, the industry’s global landscape is shifting. The trends identified in Clarivate’s 2026 medtech outlook—from procurement reforms in China to the rapid adoption of enabling technologies—are not isolated market dynamics. They are signals of a deeper restructuring in how medical devices are created, validated, and brought to market. Understanding these forces is essential for companies operating across North American borders and for policymakers seeking to strengthen regional competitiveness.

Main Analysis

1. China’s VBP Expansion: A New Benchmark for Global Pricing

China’s national volume-based procurement program has evolved from a cost-containment measure into a powerful market-structuring mechanism. The latest rounds have introduced anchor-price logic, aggressive price compression, and allocation systems that favor domestic manufacturers. For multinational medtech companies, VBP is no longer a China-specific issue. It is setting pricing expectations in other emerging markets and pressuring global portfolio strategies.

From a North American perspective, the implications are twofold. First, companies with significant exposure to the Chinese market must reassess their product positioning and value propositions. Second, the pricing pressure reinforces the need for operational efficiency and innovation in manufacturing. North American producers can mitigate margin compression by leveraging nearshoring benefits under USMCA to reduce production costs and increase supply chain responsiveness.

2. Outpatient and ASC Settings: Restructuring Procedure Dynamics

In the United States, the Centers for Medicare & Medicaid Services (CMS) has continued to expand the Ambulatory Surgical Center (ASC) Covered Procedure List, opening the door for higher-acuity procedures to move out of hospitals. This is part of a long-running shift that is now touching cardiac ablation, orthopedics, and other complex procedures. For manufacturers, this alters not only the customer base but also device design requirements, with a growing emphasis on portability, ease of use, and cost-effectiveness.

For North America, this trend accelerates the need for cross-border logistical agility. Medical devices must now be distributed to a wider array of care settings, including independent ASCs and outpatient clinics. This creates opportunities for specialized logistics providers and for manufacturing strategies that support rapid replenishment. It also influences where production is located, with proximity to major markets becoming a more critical factor.

3. Global Trade and Supply Chain Pressures: Reshaping Production Footprints

Clarivate’s report highlights that tariff exposure, geopolitical tensions, and fluctuating material costs are challenging long-standing assumptions about where devices should be produced. In response, larger manufacturers are diversifying sourcing and pursuing multi-region manufacturing footprints. This is a clear accelerant for nearshoring and reshoring across North America.

Mexico, in particular, stands to benefit as companies seek lower-cost, geographically proximate alternatives to Asia. The medical device industry in Mexico already exports billions of dollars to the United States annually, and this trend is likely to deepen. For the United States, advanced manufacturing investment in areas such as semiconductors and precision components could create new synergies with medtech production. Canada, with its strengths in materials science and digital health, is well-positioned to contribute to R&D and technology development.

4. GLP-1 Therapies: Reshaping Clinical Pathways and Device Demand

The rapid adoption of GLP-1 receptor agonists for weight management is altering patient behavior and clinical approaches. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP-1s are reducing the volume of some bariatric procedures and starting to influence demand in diabetes care, sleep apnea, and cardiovascular monitoring.

This trend has a direct impact on North American medical device manufacturers. Companies with portfolios tied to procedures that are being displaced must pivot toward complementary technologies and new therapy areas. It also underscores the importance of cross-sector innovation, as pharmaceutical and device strategies become increasingly intertwined. For the region, this represents an opportunity to lead in integrated metabolic-disease management, combining devices, digital health, and pharmaceutical partnerships.

5. Enabling Technologies: The Rise of Platform-Based Competition

Robotics, imaging, navigation, and digital workflow software are no longer adjuncts to procedures. They are becoming the centerpieces of integrated ecosystems that support clinical planning, surgical execution, and postoperative care. Clarivate notes that companies are investing heavily in platform architectures that can anchor entire service lines and unlock data-driven value propositions.

In North America, this trend reinforces the strategic importance of technology clusters. The United States remains the global leader in medical robotics and digital health innovation, while Canada contributes growing expertise in AI software and connected health. For manufacturers in Mexico, the shift toward platform-based competition means that component-level production can benefit from deeper partnerships with technology developers. The result is a more complex but potentially more valuable manufacturing ecosystem across the region.

Trade Impact

The medtech trends analyzed above are having demonstrable effects on international trade and cross-border commerce. Supply chain rebalancing is leading to increased intra-regional trade in medical devices and components. The USMCA framework provides mechanisms for tariff-free trade and regulatory cooperation, which become more valuable as companies seek to integrate their North American operations.

However, trade impacts are not uniform. China’s VBP could reduce exports for some companies while redirecting investment flows. The ASC shift creates new demand for logistics and distribution services. GLP-1 therapies may dampen demand for certain categories, affecting trade volumes in bariatric devices. For exporters and importers, agility is key. Companies that can quickly adapt their product portfolios and supply chain structures will be better positioned to capture value from these shifts.

Regional Perspective

United States

The U.S. remains the world’s largest medtech market and innovation engine. The ASC migration is creating new commercial opportunities, while the demand for enabling technologies strengthens the case for sustained investment in R&D. However, pricing pressures and global competition require U.S. manufacturers to pursue operational excellence. The reshoring of advanced manufacturing, supported by industrial policies such as the CHIPS Act and Inflation Reduction Act, could provide a foundation for a more resilient medical device supply chain.

Canada

Canada’s medtech sector is characterized by innovation in digital health, AI, and specialized medical devices. The rise of platform-based competition aligns well with Canada’s strengths in software and data analytics. However, Canada’s manufacturing base is relatively small, and the country must leverage its trade agreements to integrate more deeply into North American supply chains. Investment in R&D commercialization and workforce development will be essential.

Mexico

Mexico is the manufacturing workhorse of North American medtech. The country has attracted significant foreign direct investment, particularly in medical device assembly and precision components. The trend toward multi-region manufacturing footprints is a tailwind for Mexico, as companies seek to diversify away from Asia. Amid global supply chain disruptions, Mexico offers trade corridors, cost advantages, and proximity to the U.S. market. However, infrastructure and regulatory harmonization under USMCA will need to be addressed to fully realize this potential.

Future Outlook (2026–2030)

Over the next 3–5 years, the North American medtech landscape will undergo further transformation. The following developments are likely:

• Deeper regional integration: As supply chain pressures persist, companies will further align their manufacturing networks across the USMCA region. We expect increased cross-border investment in Mexico and reshoring in the U.S., driven by policy incentives and the need for resilience.
• Platform-based competition: Robotics, AI, and digital workflows will become the primary battlefield for medtech market share. North American firms that lead in these technologies will be able to set industry standards and capture high-value segments.
• Regulatory evolution: The convergence of devices and drugs, especially with GLP-1 therapies, will lead to new regulatory frameworks. Cross-border harmonization under USMCA will become more critical to facilitate approvals and ensure market access.
• Supply chain transparency: Companies will invest in digital tools, including AI, to gain end-to-end visibility of their supply chains. This will enhance capacity planning and risk mitigation.
• Expansion of outpatient care: The shift to ASCs and outpatient settings will continue, particularly in the U.S. This will drive demand for smaller, more portable devices and disrupt traditional distribution models.
• Energy and infrastructure considerations: The growth of advanced manufacturing will place new demands on energy infrastructure, especially in Mexico. Industrial parks and border infrastructure will require investment to keep pace with nearshoring.

Conclusion

The medtech industry’s 2026 trends are not merely market indicators; they are catalysts for a new industrial and trade strategy across North America. The region’s ability to adapt to these changes will determine its global competitiveness in one of the most dynamic sectors of the economy. By leveraging USMCA’s framework, investing in enabling technologies, and embracing nearshoring, the United States, Canada, and Mexico can strengthen their positions in the global medtech market. For manufacturers and investors, the time to act is now.

Key Takeaways

• China’s VBP expansion is reshaping global pricing and creating pressure to diversify markets.
• The shift to outpatient and ASC settings is transforming device design and distribution.
• Supply chain pressures are accelerating nearshoring and regional integration in North America.
• GLP-1 therapies are altering demand for certain medical devices and creating cross-sector opportunities.
• Enabling technologies are driving platform-based competition, with strategic implications for manufacturing value chains.
• USMCA is becoming an increasingly central tool for ensuring regulatory compatibility and trade facilitation.

SEO Keywords

• Medtech Trends 2026
• North America medical device manufacturing
• USMCA medical device trade
• Supply chain resilience medtech
• Nearshoring in Mexico
• ASC procedure growth
• GLP-1 impact on medical devices
• Platform-based competition medtech
• Cross-border trade medical devices
• North American industrial policy

Sources

• Clarivate, “Medtech Trends to Watch in 2026” – Link